 | |
| Names | |
|---|---|
| Preferred IUPAC name (3R)-2′-[(4-Bromo-2-fluorophenyl)methyl]-1′H-spiro[pyrrolidine-3,4′-pyrrolo[1,2-a]pyrazine]-1′,2,3′,5(2′H)-tetrone | |
| Identifiers | |
3D model (JSmol) | |
| ChemSpider |
|
| UNII | |
| |
| |
| Properties | |
| C17H11BrFN3O4 | |
| Molar mass | 420.189 g/mol |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Ranirestat (also known asAS-3201) is analdose reductase inhibitor being developed for the treatment ofdiabetic neuropathy byDainippon Sumitomo Pharma andPharmaKyorin. It has been grantedorphan drug status. The drug is to be used orally.
A Canadian Phase IIIclinical trial has been completed. Phase III trials in Europe and the US started in June 2009 and are expected to complete in April 2013.
Ranirestat is aldose reductase inhibitor that acts by reducing sorbitol accumulation in cells. Aldose reductase is an enzyme that catalyzes one of the steps in sorbitol (polyol) pathway which is responsible for formation of fructose from glucose. Aldose reductase activity is increased, parallel to glucose blood levels, in tissues that are not insulin sensitive, including lenses, peripheral nerves and renal glomeruli. Sorbitol does not diffuse through cell membranes easily and therefore accumulates in these tissues, causing osmotic damage, leading to retinopathy and neuropathy.
Results from a Canadian double-blind, placebo-controlled biopsy Phase III clinical trial, involving total of 549 patients with diabetic sensorimotor polyneuropathy (DSP) randomly assigned to treatment with placebo or 10, 20, or 40 mg/day ranirestat for 52 weeks, showed that ranirestat appears to have effect on motor nerve function in mild to moderate DSP, but failed to show statistically significant difference in sensory nerve function. Efficacy of ranirestat was evaluated by nerve conduction studies, the modified Toronto Clinical Neuropathy Score (mTCNS), and quantitative sensory tests (QSTs).[1]
 | This articleneeds additional citations forverification. Please helpimprove this article byadding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Ranirestat" – news ·newspapers ·books ·scholar ·JSTOR(September 2011) (Learn how and when to remove this message) |
 | Thisdrug article relating to thegastrointestinal system is astub. You can help Wikipedia byexpanding it. |
